Create a narrative

Day One Biopharmaceuticals Community

NasdaqGS:DAWN Community

1 Narratives written by author
0 Comments on narratives written by author
5 Fair Values set on narratives written by author

Create a narrative

Day One Biopharmaceuticals

AN

AnalystConsensusTarget

Consensus Narrative from 8 Analysts

FDA Approval And Ipsen Licensing Will Expand Pediatric Treatment Options

Key Takeaways FDA approval and the launch of OJEMDA boost long-term revenue growth, addressing unmet medical needs and strong market uptake in pediatric glioma. The Ipsen licensing deal and DAY301 acquisition enhance revenue streams and earnings growth through geographic expansion and pipeline diversification.

US$30.75

FV

75.0% undervalued

44.46%

Revenue growth p.a.

0

0

0

New